When working on a rare disease program, there are far reaching benefits to conducting a natural history (NH) study. In this article, Allucent’s Dr. Jovana Vlajkovic-Josic was interviewed by Melissa Fassbender from Outsourcing-Pharma.
Read the full version of Natural history studies ‘essential’ for rare disease drug development.
{{cta(‘1a2282be-4b8f-48c8-8707-3fd5d027c84c’)}}
About Allucent as a Rare Disease CRO
Allucent is Helping Create a Healthier World as a global, mid-sized CRO offering flexible, innovative, and highly personalized clinical solutions to pharmaceutical, biotechnology, and life science companies. We have conducted over 100 rare disease studies. To learn more about our rare disease expertise, visit our Rare Disease Center of Excellence service page.